EMOL Health Leadership had the opportunity to attend the NCCN 2025 Annual Conference and present the results of a study on Myelosuppression and Healthcare Utilization in Community Oncology Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) Receiving First-Line Therapy with or without Trilaciclib. The study was an expansion on previous work that had focused on Trilaciclib use in extensive-stage small cell lung cancer patients. The study was completed in conjunction with Dr. Ajeet Gajra, MD and Pharmacosmos (formerly G1 Therapeutics).
The publication (HSR25-156) is available here.
